FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

washington,	D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MCGLYNN MARGARET G (Last) (First) (Middle)							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									ship of Reporting Pe applicable) rector ficer (give title low)		10% Ov Other (s below)	vner
C/O VERTEX PHARMACEUTICALS INCORPORATED							Earlio 22	est Tra	nsactio	n (Mo	nth/Day/Year)								
50 NORTHERN AVENUE							dmer	nt, Date	e of Ori	ginal F	Filed (Month/D	Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	N M	ÍΑ	02210)	_								X	•					
(City)	(S	tate)	(Zip)																
		Tab	le I -	Non-Deri	vativ	e Sec	urit	ies A	cquir	ed, [Disposed (of, or E	Benefi	cially	Owned	t			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		Beneficia Owned F		ies ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock				03/31/20)22	22			M		5,000	A	\$12	7.54	6,	6,099		D	
Common	Common Stock			03/31/20)22	22					1,019	D	\$261 .	28(2)(3)	5,080			D	
Common	nmon Stock 03/31/202)22	2		S ⁽¹⁾		2,970	D	\$262.	37(3)(4)	2,110			D			
Common	Stock			03/31/20)22				S ⁽¹⁾		1,011	D	\$262 .	97(3)(5)	1,099 D				
		T	able								sposed of s, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, :h/Day/Year)	4. Transa Code (8)	saction (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ivative urities uired or posed O) tr. 3, 4	6. Date Exel Expiration I (Month/Day			Amoun Securit Underly Derivat	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Price of erivative curity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	y Director In (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amo or Num of Shar	ber					
Common Stock (right to	\$127.54	03/31/2022			M			5,000		(6)	05/31/2025	Commo		00	127.54	10,000	, [D	

Explanation of Responses:

- 1. Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$261.28 (range \$260.78 to \$261.73).
- 3. Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$262.37 (range \$261.79 to \$262.78).
- 5. Open market sales reported on this line occurred at a weighted average price of \$262.97 (range \$262.80 to \$263.34).
- 6. Fully vested

Remarks:

/s/ Sabrina Yohai, Attorney-in-

04/04/2022

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.